The long-lasting anti-tumor activity of cisplatin affecting the sustainable systemic immune alteration may improve distant-disease free survival of triple-negative breast cancer in patients with a substantial residual tumor following preoperative chemotherapy: A retrospective analysis with translational research.

Ayane Yamaguchi,Kosuke Kawaguchi,Hiroshi Ishiguro,Tatsuki R. Kataoka,Masae Torii,Chenfeng He,Nobuko Kawaguchi-Sakita,Masahiro Kawashima,Masahiro Takada,Eiji Suzuki,Masakazu Toi

The long-lasting anti-tumor activity of cisplatin affecting the sustainable systemic immune alteration may improve distant-disease free survival of triple-negative breast cancer in patients with a substantial residual tumor following preoperative chemotherapy: A retrospective analysis with translational research.

2020

Ayane Yamaguchi
Kosuke Kawaguchi
Hiroshi Ishiguro
Tatsuki R. Kataoka
Masae Torii
Chenfeng He
Nobuko Kawaguchi-Sakita
Masahiro Kawashima
Masahiro Takada
Eiji Suzuki
Masakazu Toi

e12631Background: Residual disease after preoperative chemotherapy is known to be a poor prognostic factor in triple-negative breast cancer (TNBC). Perioperative use of cisplatin (CDDP) is a well-k...

Keywords:

Triple-negative breast cancer
Translational research
Cisplatin
Immune system
Internal medicine
retrospective analysis
Oncology
long lasting
Medicine
Pathology
in patient
antitumor activity
preoperative chemotherapy
Breast cancer
Perioperative
Disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations